Niels J Brouwer1, John B A G Haanen2, Martine J Jager1. 1. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: To report a case of severe ocular rosacea following ipilimumab plus nivolumab treatment in a patient with metastatic malignant skin melanoma. METHODS: Case report and review of the literature. RESULTS: A 68-year-old male with newly diagnosed metastatic malignant cutaneous melanoma was treated with first-line ipilimumab plus nivolumab, which resulted in a partial response. Four months after initiation of treatment, the patient developed red eyelids and conjunctivae, with painful gritty eyes, limiting his capacity to read. Following a diagnosis of severe ocular rosacea and dry eyes, treatment including corticosteroids, antimicrobial agents, and eyelid hygiene was started, and within 3 months, the ocular complaints resolved. CONCLUSION: Treatment with checkpoint inhibitor immunotherapy for metastatic melanoma may trigger several ocular immune-related adverse events. This case describes severe ocular rosacea as an adverse event following ipilimumab plus nivolumab treatment.
PURPOSE: To report a case of severe ocular rosacea following ipilimumab plus nivolumab treatment in a patient with metastatic malignant skin melanoma. METHODS: Case report and review of the literature. RESULTS: A 68-year-old male with newly diagnosed metastatic malignant cutaneous melanoma was treated with first-line ipilimumab plus nivolumab, which resulted in a partial response. Four months after initiation of treatment, the patient developed red eyelids and conjunctivae, with painful gritty eyes, limiting his capacity to read. Following a diagnosis of severe ocular rosacea and dry eyes, treatment including corticosteroids, antimicrobial agents, and eyelid hygiene was started, and within 3 months, the ocular complaints resolved. CONCLUSION: Treatment with checkpoint inhibitor immunotherapy for metastatic melanoma may trigger several ocular immune-related adverse events. This case describes severe ocular rosacea as an adverse event following ipilimumab plus nivolumab treatment.
Authors: Toni K Choueiri; Mayer N Fishman; Bernard Escudier; David F McDermott; Charles G Drake; Harriet Kluger; Walter M Stadler; Jose Luis Perez-Gracia; Douglas G McNeel; Brendan Curti; Michael R Harrison; Elizabeth R Plimack; Leonard Appleman; Lawrence Fong; Laurence Albiges; Lewis Cohen; Tina C Young; Scott D Chasalow; Petra Ross-Macdonald; Shivani Srivastava; Maria Jure-Kunkel; John F Kurland; Jason S Simon; Mario Sznol Journal: Clin Cancer Res Date: 2016-05-11 Impact factor: 12.531
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Jeffrey S Weber; Omid Hamid; Scott D Chasalow; Dianna Y Wu; Susan M Parker; Susan Galbraith; Sacha Gnjatic; David Berman Journal: J Immunother Date: 2012-01 Impact factor: 4.456